HER2陽性進行乳がんに対するトラスツズマブ エムタンシン

Vermaら（Mon,）がこの問題を研究した。

www.synapsesocial.com/papers/69d7bd926c394ad7d0bed8c4 — DOI: https://doi.org/10.1056/nejmoa1209124

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine· 2012 · 362 citations
2. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy· 2010 · 763 citations
3. New Guidelines to Evaluate the Response to Treatment in Solid Tumors· 2000 · 15,703 citations
4. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.· 1997 · 1,754 citations
5. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene· 1987 · 11,719 citations